Subscribe
The prospect of any cost savings has been fueling efforts to establish a pathway for follow-on biopharmaceuticals.
Legal Forum: Patenting Strategies to Delay Biogeneric Competition
Final Word: Omnitrope's Approval: What Does It Mean For Other Generics?
Final Word: The US is Falling Behind on Generic Biopharmaceuticals
The Best Targets for Biogenerics